Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Non-Postoperative Pain Management Market Set for Significant Growth During the Forecast Period (2026–2036), Driven by Novel Non-Opioid Therapies | DelveInsight

globenewswire.com
SCLX Scilex Holding Company's drug ELYXYB is mentioned as a driver for growth in the non-postoperative pain management market, indicating positive market reception and potential for increased sales. VRTX Vertex Pharmaceuticals' Suzetrigine is listed as a drug under development for non-postoperative pain management, suggesting potential future market contribution and growth for the company in this therapeutic area. PCRX Pacira BioSciences' drug PCRX-201 is mentioned as being under development for non-postoperative pain management, indicating potential future growth and market presence for the company in this sector.

Non-Postoperative Pain Management Market Set for Significant Growth During the Forecast Period (2026–2036), Driven by Novel Non-Opioid Therapies | DelveInsight New York, USA, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Non-Postoperative Pain Management Market Set for Significant Growth During the Forecast Period (2026–2036), Driven by Novel Non-Opioid Therapies | DelveInsight

The non-postoperative pain management market is witnessing steady growth, driven by the increasing prevalence of acute and chronic pain conditions, rising demand for effective non-surgical pain therapies, and greater emphasis on opioid-sparing treatment strategies. Advances in non-opioid analgesics, targeted therapies, and innovative drug delivery technologies are expanding the treatment landscape. In addition, the expected launch of emerging therapies such as TK-254Rx (esflurbiprofen transdermal) (Teikoku Pharma), RizaFilm (rizatriptan) (Gensco Pharma), ELYXYB (Scilex Holding Company), and others will further propel the market growth.

Recently published Non-Postoperative Pain Management Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative pain management emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Non-Postoperative Pain Management Market Summary

Discover what is the future of the non-postoperative pain management treatment market @ https://www.delveinsight.com/report-store/non-postoperative-pain-management-market

Key Factors Driving the Growth of the Non-Postoperative Pain Management Market

Aparna Thakur, Project Manager of Forecasting at DelveInsight, said that adjunct therapies such as ketamine, anticonvulsants, and topical agents are projected to witness moderate but growing adoption, supported by the shift toward multimodal analgesia (MMA). In parallel, non-pharmacological approaches, including physical therapy, cold application, and rehabilitation strategies, are expected to gain steady traction, particularly for musculoskeletal and injury-related pain, reinforcing a broader move toward integrated pain management.

Non-Postoperative Pain Management Market Analysis

Learn more about the non-postoperative pain management therapeutics market @ US Non-Postoperative Pain Management Treatment Market

Non-Postoperative Pain Management Competitive Landscape

Some of the non-postoperative pain management drugs under development include TK-254Rx (esflurbiprofen transdermal) (Teikoku Pharma), RizaFilm (rizatriptan) (Gensco Pharma), ELYXYB (Scilex Holding Company), CT001 (Cessatech A/S), LTG-001 and LTG-321 (Latigo Biotherapeutics), PCRX-201 (Pacira BioSciences), Suzetrigine (Vertex Pharmaceuticals), and others.

Teikoku Pharma’s TK-254Rx is an investigational 1.5% s-flurbiprofen hydrogel patch developed for the treatment of acute minor sports injuries. Designed with a favorable safety profile, it is intended for once-daily use for up to seven days. The patch incorporates proprietary Hydrohesive technology and is currently being studied for its potential to relieve pain associated with acute strains, sprains, and contusions.

Gensco Pharma’s RizaFilm is a proprietary oral thin-film formulation containing rizatriptan benzoate for the treatment of migraine. The rapidly dissolving film can be taken without water, offering convenient administration and prompt symptom relief. Rizatriptan has demonstrated clinical efficacy in alleviating migraine-related symptoms, including nausea, photophobia, and phonophobia. In May 2025, Gensco Pharma obtained the global intellectual property and commercialization rights for the only rizatriptan oral dissolving film (ODF), which is marketed as RizaFilm in the United States and as RizaFilm/RizaPort in international markets.

Latigo Biotherapeutics’ LTG-001 is an investigational oral, non-opioid small-molecule therapy designed to selectively and potently inhibit Nav1.8 for the treatment of moderate to severe acute pain. The candidate demonstrated positive results in a randomized, placebo- and active comparator-controlled trial involving 343 patients undergoing abdominoplasty. Following discussions with the FDA, the study may qualify as one of the two pivotal, adequate, and well-controlled trials needed to support regulatory approval for moderate to severe acute pain, including postoperative pain. The trial achieved its primary endpoint of SPID48, with the high-dose LTG-001 regimen (450 mg loading dose followed by 300 mg twice daily) producing a statistically significant 62.1-point reduction in pain versus placebo.

In addition, the high-dose regimen delivered approximately 50% greater analgesic efficacy than the opioid comparator, Vicodin. Patients receiving high-dose LTG-001 experienced meaningful pain relief as early as 52 minutes after dosing, compared with 83 minutes in the Vicodin arm. More than half (52.3%) of patients treated with high-dose LTG-001 remained opioid-free throughout the 48-hour treatment period. To date, LTG-001 has demonstrated a generally favorable tolerability profile.

The anticipated launch of these emerging non-postoperative pain management therapies are poised to transform the non-postoperative pain management market landscape in the coming years. As these cutting-edge non-postoperative pain management therapies continue to mature and gain regulatory approval, they are expected to reshape the non-postoperative pain management market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about Non-Postoperative Pain Management treatment options and survival rates comparison, visit @ Malignant Non-Postoperative Pain Management Therapeutic Market

Recent Developments in the Non-Postoperative Pain Management Market

Non-Postoperative Pain Management Epidemiology Segmentation

The non-postoperative pain management epidemiology section provides insights into the historical and current non-postoperative pain management patient pool and forecasted trends for the leading markets. Across the 7MM, non-postoperative pain burden is strongly driven by a high volume of injury- and trauma-related cases, with the US alone reporting approximately 40 million injury-related emergency department visits (2020), accounting for about 12% of total population exposure.

The non-postoperative pain management market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

Download the report to understand the emerging trends in the non-postoperative pain management treatment @ Non-Postoperative Pain Management Treatment Options

Scope of the Non-Postoperative Pain Management Market Report

Discover more about next-generation non-postoperative pain management drugs @ Non-Postoperative Pain Management Clinical Trials

Table of Contents

Related Reports

Postoperative Pain Market

Postoperative Pain Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key postoperative pain companies, including Taiwan Liposome Company (TLC), Teikoku Pharma USA, Novartis Pharmaceuticals, Concentric Analgesics, Mati Therapeutics, Arthritis Innovation Corporation, MedinCell, Surface Ophthalmics, Salvat Laboratories, Grünenthal, Vertex Pharmaceuticals, Formosa Pharmaceuticals, Oculis, Neumentum Pharmaceuticals, Charleston Laboratories, and others.

Postoperative Acute Pain Market

Postoperative Acute Pain Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key postoperative acute pain companies, including Taiwan Liposome Company (TLC), Teikoku Pharma, Concentric Analgesics, Arthritis Innovation Corporation, MedinCell, Surface Ophthalmics, Salvat Laboratories, Vertex Pharmaceuticals, Formosa Pharmaceuticals, Avenue Therapeutics, Cali Pharmaceuticals LLC, and others.

Non-Postoperative Acute Pain Market

Non-Postoperative Acute Pain Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key non-postoperative acute pain companies, including Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others.

Acute Pain Market

Acute Pain Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute pain companies, including Hyloris Pharmaceuticals, AFT Pharmaceuticals, Formosa Pharmaceuticals, Concentric Analgesics, Vivozon, Vertex Pharmaceuticals, Taiwan Liposome Company (TLC), Medical Developments International (MVP), Neumentum Pharmaceuticals, Charleston Laboratories, AcelRx Pharmaceuticals, Teikoku Pharma USA, PainReform, Nevakar, and others.

Moderate-to-Severe Acute Pain Market

Moderate-to-Severe Acute Pain Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key moderate-to-severe acute pain companies, including Gensco Pharma, IntelGenx, Cali Biosciences, PainReform, Oculis Pharma, MedinCell, Arthritis Innovation Corporation (AIC), Neumentum, Tris Pharma, Viatris, Xgene Pharmaceutical, Taiwan Liposome Company (TLC BioSciences), Allodynic Therapeutics, Latigo Biotherapeutics, Concentric Analgesics, Allay Therapeutics and Maruishi Pharmaceutical, Halia Therapeutics, Teikoku Pharma, Cessatech A/S, Vaneltix Pharma, Biohaven Pharmaceuticals, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.